secwatch.observer — SEC 8-K summary
======================================

Issuer:     Oncternal Therapeutics, Inc. (—)
CIK:        0001260990
Form:       8-K
Filed at:   2023-10-06T23:59:59+00:00
Accession:  0000950170-23-052419
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncternal gets 180-day Nasdaq extension to April 1, 2024 to regain bid price compliance
--------------------------------------------------------------------------------

- Nasdaq granted an additional 180 days, to April 1, 2024, to meet the $1.00 minimum bid price rule.
- Original non-compliance notice issued April 4, 2023 after bid closed below $1.00 for 30 consecutive days.
- Stockholders approved a reverse stock split (1:5 to 1:30) at June 28, 2023 annual meeting to cure deficiency.
- If not compliant by April 1, 2024, Nasdaq will issue delisting notice; company may appeal.
- No assurance compliance will be regained or that other listing requirements will be maintained.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1260990/000095017023052419/0000950170-23-052419-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1260990/000095017023052419/onct-20231003.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-052419

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer